Samsung Biologics has launched a drug screening service using organoids

This marks its entry into contract research alongside its existing biologics development and manufacturing services.

The service, named Samsung Organoids, focuses on screening anti-cancer drug candidates derived from cancer cells.

Organoids are three-dimensional models created from stem or tissue cells, designed to replicate human organ functions.

These models are increasingly used in the pharmaceutical industry due to their relevance to patient conditions.

Samsung Biologics reported that its organoid services comply with Good Manufacturing Practice standards and is supported by 359 regulatory approvals, including from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Samsung aims to grow in the rising organoid market, projected to hit US$3.3 billion by 2030, as it adds preclinical research to its portfolio.

🔗 Source: The Korea Times

🧠 Food for thought

1️⃣ Regulatory shifts create perfect timing for organoid technology

Samsung Biologics’ launch of organoid-based drug screening coincides strategically with significant regulatory changes in drug development.

The FDA announced plans in April 2025 to phase out animal testing requirements for drug development, initially focusing on monoclonal antibodies before expanding to other drugs 1.

This policy shift has created immediate market opportunity for alternatives like organoids, which provide up to 85% patient similarity while addressing ethical concerns about animal testing.

The transition to human-relevant testing methods has garnered bipartisan congressional support, establishing a regulatory pathway for technologies like Samsung’s organoid platform 2.

These regulatory changes directly contribute to the projected 22% annual growth of the patient-derived organoid market from $1 billion in 2024 to $3.3 billion by 2030.

2️⃣ Scientific breakthroughs enable commercial viability of organoids